Free tool
Find any stock
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
86 stocks worldwide match these filters · market cap, largest first. Clear filters
Data as of Aug 26, 2026 · updates nightly, Mon–Sat
| Ticker | Company | Theme | Market cap (USD) | Price | vs 52-week high | 1M return |
|---|---|---|---|---|---|---|
| LEGN | Legend Biotech Corporation | Cell therapy | $4.14B | $21.30 | −43.20% | +10.53% |
| IOVA | Iovance Biotherapeutics, Inc. | Cell therapy | $3.82B | $8.44 | −9.83% | +72.24% |
| MSB.AX | Mesoblast Limited | Cell therapy | $2.25B | 2.40 AUD | −27.64% | +16.26% |
| MESO | Mesoblast Limited | Cell therapy |
Every company we cover sits in at least one of these lists. Each one opens as a full table of its members, ordered by market value.
The 11 business sectors every covered company is classified into.
The 20 narrower groupings we keep for parts of the market that do not split neatly by sector.
Price chart, technicals, money flow, fundamentals and an AI-written read — one page per stock, $9.90 each. Already know the symbol?
| $2.23B |
| $17.19 |
| −20.05% |
| +18.06% |
| VCEL | Vericel Corporation | Cell therapy | $2.21B | $43.22 | −12.37% | −4.63% |
| BLFS | BioLife Solutions, Inc. | Cell therapy | $1.82B | $37.22 | −2.31% | +24.94% |
| VOR | Vor Biopharma Inc. | Cell therapy | $1.30B | $24.01 | −52.17% | +23.51% |
| SANA | Sana Biotechnology, Inc. | Cell therapy | $1.23B | $4.10 | −37.40% | +25.00% |
| IMMX | Immix Biopharma, Inc. | Cell therapy | $968.90M | $14.47 | −4.17% | +66.51% |
| SYNC.L | Syncona Limited | Cell therapy | $923.83M | 111.40 GBP | 0.00% | +5.69% |
| CYRX | Cryoport, Inc. | Cell therapy | $846.85M | $16.72 | −2.79% | +10.36% |
| ALLO | Allogene Therapeutics, Inc. | Cell therapy | $749.72M | $2.17 | −51.35% | +24.00% |
| PROK | ProKidney Corp. | Cell therapy | $690.59M | $1.73 | −50.29% | +12.34% |
| AUTL | Autolus Therapeutics plc | Cell therapy | $649.44M | $2.44 | −5.43% | +67.12% |
| ARTV | Artiva Biotherapeutics, Inc. | Cell therapy | $575.44M | $11.77 | −19.00% | +14.05% |
| KYTX | Kyverna Therapeutics, Inc. | Cell therapy | $546.70M | $8.84 | −35.33% | +11.62% |
| CABA | Cabaletta Bio, Inc. | Cell therapy | $545.94M | $3.22 | −23.88% | +18.38% |
| 0JDK.L | Iovance Biotherapeutics, Inc. | Cell therapy | $501.00M | $8.36 | −1.42% | +1.91% |
| 4592.T | SanBio Company Limited | Cell therapy | $495.75M | 1,024.00 JPY | −74.34% | +10.58% |
| CAPR | Capricor Therapeutics, Inc. | Cell therapy | $481.97M | $8.29 | −79.46% | +18.43% |
| 005690.KS | Pharmicell Co., Ltd. | Cell therapy | $472.35M | 10,830.00 KRW | −48.79% | +10.85% |
| 0HX7.L | Adicet Bio, Inc. | Cell therapy | $415.26M | $9.03 | −59.69% | +0.56% |
| IPSC | Century Therapeutics, Inc. | Cell therapy | $392.93M | $2.17 | −28.62% | +3.83% |
| LYEL | Lyell Immunopharma, Inc. | Cell therapy | $379.58M | $15.49 | −65.58% | +19.52% |
| ALCLS.PA | Cellectis S.A. | Cell therapy | $345.47M | 2.76 EUR | −43.06% | +9.63% |
| CLLS | Cellectis S.A. | Cell therapy | $344.40M | $3.42 | −37.59% | +18.34% |
| 219A.T | HEARTSEED INC | Cell therapy | $338.82M | 2,365.00 JPY | −38.65% | +36.94% |
| FATE | Fate Therapeutics, Inc. Common Stock | Cell therapy | $305.54M | $2.55 | −21.05% | +4.94% |
| RNAC | Cartesian Therapeutics, Inc. | Cell therapy | $304.37M | $10.38 | −12.03% | +33.25% |
| 4894.T | Cuorips Inc. | Cell therapy | $291.63M | 5,670.00 JPY | −54.27% | +37.29% |
| LCTX | Lineage Cell Therapeutics, Inc. | Cell therapy | $275.67M | $1.13 | −45.93% | +9.71% |
| 4593.T | Healios K.K. | Cell therapy | $239.21M | 283.00 JPY | −54.94% | +25.22% |
| 7774.T | Japan Tissue Engineering Co., Ltd. | Cell therapy | $223.27M | 875.00 JPY | −2.56% | +41.82% |
| NKTX | Nkarta, Inc. | Cell therapy | $194.10M | $2.71 | −27.15% | +19.91% |
| 504A.T | Innovacell Inc. | Cell therapy | $156.32M | 555.00 JPY | −55.53% | +17.34% |
| OCC.AX | Orthocell Limited | Cell therapy | $152.21M | 0.78 AUD | −51.25% | +9.86% |
| MXCT | MaxCyte, Inc. | Cell therapy | $139.33M | $1.35 | −27.61% | +32.35% |
| 0HIY.L | Atara Biotherapeutics, Inc. | Cell therapy | $124.82M | $9.92 | −47.95% | +1.60% |
| ATRA | Atara Biotherapeutics, Inc. | Cell therapy | $98.77M | $9.84 | −48.60% | +27.63% |
| ACET | Adicet Bio, Inc. | Cell therapy | $84.25M | $9.00 | −48.39% | +11.66% |
| INKT | MiNK Therapeutics, Inc. | Cell therapy | $60.32M | $11.38 | −32.98% | +7.46% |
| V3V.DE | FamiCord AG | Cell therapy | $58.21M | 2.85 EUR | −62.75% | −3.06% |
| 7776.T | CellSeed Inc. | Cell therapy | $56.74M | 234.00 JPY | −54.83% | +13.59% |
| 4896.T | K Pharma,Inc. | Cell therapy | $56.45M | 773.00 JPY | −18.55% | +4.46% |
| 4584.T | Kidswell Bio Corporation | Cell therapy | $55.83M | 180.00 JPY | −43.75% | +28.57% |
| HEMO.L | Hemogenyx Pharmaceuticals Plc | Cell therapy | $53.78M | 580.00 GBP | −67.78% | −17.08% |
| ALA.AX | Arovella Therapeutics Limited | Cell therapy | $52.84M | 0.06 AUD | −50.40% | −3.13% |
| ALPS | Alps Group Inc | Cell therapy | $52.42M | $0.31 | −89.14% | −32.74% |
| TCRX | TScan Therapeutics, Inc. | Cell therapy | $51.87M | $0.79 | −69.12% | +3.35% |
| 7096.T | StemCell Institute Inc. | Cell therapy | $48.78M | 772.00 JPY | −24.68% | +6.63% |
| TVGN | Tevogen Inc. | Cell therapy | $44.34M | $6.97 | −85.92% | +25.13% |
| 2370.T | MEDINET Co., Ltd. | Cell therapy | $44.25M | 25.00 JPY | −41.86% | +4.17% |
| 3750.T | ADR Biomedical Holdings Inc. | Cell therapy | $43.59M | 773.00 JPY | −18.63% | −0.64% |
| 4880.T | CellSource Co., Ltd. | Cell therapy | $43.15M | 347.00 JPY | −46.45% | +10.51% |
| DTSQ | DT Cloud Star Acquisition Corporation | Cell therapy | $41.39M | $11.33 | −12.17% | −0.18% |
| 4893.T | Noile-Immune Biotech Inc. | Cell therapy | $40.36M | 148.00 JPY | −31.80% | +3.50% |
| PTG.WA | Poltreg S.A. | Cell therapy | $36.84M | 25.20 PLN | −19.23% | +14.03% |
| 4892.T | Cyfuse Biomedical K.K. | Cell therapy | $36.02M | 571.00 JPY | −25.26% | +10.66% |
| CCEL | Cryo-Cell International, Inc. | Cell therapy | $34.67M | $4.30 | −14.17% | +30.30% |
| ESLA | Estrella Immunopharma, Inc. | Cell therapy | $31.97M | $0.73 | −76.75% | −5.48% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.
Size bands, from the largest companies down to the smallest we cover.
The 23 listing venues our coverage spans, across the Americas, Europe and Asia-Pacific.
5 lists built on a single stated criterion, such as paying a dividend or trading near a 52-week high.
The largest one day percentage moves in either direction, among the mid, large and mega cap companies we cover.